Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 GP3 | DOI: 10.1530/endoabs.63.GP3

ECE2019 Guided Posters Adrenal and Neuroendocrine - Tumour (14 abstracts)

ProGRP is an effective marker for disease monitoring in lung carcinoids with non-informative chromogranin A: Lessons from clinical practice

Kira Oleinikov 1 , Simona Grozinsky-Glasberg 1 , David J Gross 1 , Hovav Nechushtan 2 , Tamar Peretz 2 , Ophra Maimon 2 & Beni Nisman 2

1Neuroendocrine Tumor Unit, Hadassah-Hebrew University Medical Center Endocrinology & Metabolism Department, Jerusalem, Israel; 2Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Introduction: The histologic classification of lung carcinoids (LCs) as typical (TCs) and atypical (ACs) highlights its role as major prognostic factor for these patients. However, in the absence of sensitive biomarkers to effectively predict tumor behavior, long-term imaging surveillance is recommended for disease monitoring. Limited data suggest that progastrin-releasing peptide (ProGRP) may have diagnostic & monitoring utility in LCs.

Aim(s): To evaluate the possible role of ProGRP, in addition to chromogranin A (CgA), as a biomarker for LCs surveillance.

Materials and methods: Retrospective analysis of consecutive LCs patients treated in an ENETS Center of Excellence with regard to clinico-pathological parameters, treatment outcomes and their correlation with ProGRP and CgA.

Results: Thrity-five patients (pts) were studied (23 women; median age of 62y with a median follow up of 47 m). TCs and ACs were diagnosed in 43 and 57% of pts, respectively. 9 pts (26%) were defined as DIPNECH. The disease was localized in 31% & metastatic in 69% of cases. 71% of pts were already pretreated at the time of the first ProGRP evaluation. Disease status at first ProGRP measurement was: no evidence of disease (NED, 20%), stable disease (SD, 23%), progressive disease (PD, 57%). The NED group had normal ProGRP & CgA. In the SD group, ProGRP was increased in 62% vs 38% increase in CgA, while in the PD group 70% had increased ProGRP vs 35% with elevated CgA. Overall, ProGRP was increased in 50% of pts with evidence of disease, all with normal CgA.

Conclusion: ProGRP seems to be a valuable biomarker for monitoring patients with LCs, mainly when CgA is non-informative. Larger series including prospective long-term follow-up are needed to establish ProGRP’s specific role in monitoring disease activity in LCs pts.

Keywords: progrp, lung carcinoids, biomarkers.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.